Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Clinical trial NCT06709859 · RECRUITING

Trial details

NCT number: NCT06709859
Sponsor: Shandong Public Health Clinical Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung

Start date: 2025-05-01
Primary completion: 2026-05-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.